Towards a personalised clinical management of oncologic patients with acute kidney injury associated to immunecheckpoint inhibitors
Lombady partner:
- Laura Cosmai, ASST Fatebenefratelli Sacco
|
Pathology of interest: |
Acute kidney injury |
|
Area of research: |
Oncology |
|
Start date: |
01 April 2023 |
|
End date: |
31 March 2026 |
|
Funding: |
€ 102.800,00 |
|
Project partners: |
Hospital Vall d’Hebron. Vall d´Hebron Institut de Recerca (VHIR), Barcelona, Spain
Medical University of Warsaw, Department of Nephrology Dialysis and Internal Medicine, Poland ASST Fatebenefratelli Sacco, Nephrology and Dialysis Unit, Italy Hannover Medical School,Department of Nephrology and Hypertension, Germany Universitat Politècnica de Catalunya(UPC), Dept.of Automatic Control, Spain Uppsala Biomedical Centre, Department of Public Health and Caring Sciences, Uppsala University, Sweden Faculty of Medicine, Bezmialem Vakif University, Turkey |
Treatment with immune checkpoint inhibitors (ICIs) has led to increased survival rates of cancer patients, who were previously untreatable, by favouring an immune response against tumour cells. ICIs action is not selective and may cause immune-related adverse events. Up to 29% of cancer patients, who receive ICIs treatment, develop acute kidney injury (AKI) secondary to ICIs use (ICI-AKI), and acute tubulointerstitial nephritis (ATIN) is the most frequent lesion. ICI-AKI is a serious complication that increases the risk of AKI recurrence after ICIs rechallenge and mortality. The diagnosis of ICI-AKI is performed by a kidney biopsy, which is highly invasive. We will collect retrospective and prospective demographic and clinical data of ICI-AKI patients as well as urine, blood and kidney tissue samples of ICI treated cancer patients during two years to identify novel biomarkers related to immune response to avoid kidney biopsy. This approach will allow personalising clinical management of these patients and improving their quality of life.